Vancomycin antibiotic powder — Competitive Intelligence Brief

Vancomycin antibiotic powder (Vancomycin antibiotic powder) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: glycopeptide antibiotic. Area: Infectious Disease.

phase 3 glycopeptide antibiotic cell wall precursors Infectious Disease Small molecule

Target snapshot

Vancomycin antibiotic powder (Vancomycin antibiotic powder) — Major Extremity Trauma Research Consortium. Vancomycin works by inhibiting cell wall synthesis in bacteria, ultimately leading to cell lysis and death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vancomycin antibiotic powder TARGET	Vancomycin antibiotic powder	Major Extremity Trauma Research Consortium	phase 3	glycopeptide antibiotic	cell wall precursors
Vancomycin inhalation powder	Vancomycin inhalation powder	Savara Inc.	phase 3	glycopeptide antibiotic	cell wall precursors
Vancomycin oral liquid	Vancomycin oral liquid	Astellas Pharma Europe B.V.	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors
Vancomycin (or equivalent)	Vancomycin (or equivalent)	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors
Vancomycin capsules	Vancomycin capsules	Astellas Pharma Europe B.V.	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors
Vancomycin 1.1%	Vancomycin 1.1%	Kurobe LLC	phase 3	glycopeptide antibiotic	D-alanyl-D-alanine terminus of cell wall precursors
Vancomycin / Linezolid	Vancomycin / Linezolid	Durata Therapeutics Inc., an affiliate of Allergan plc	phase 3	glycopeptide antibiotic / oxazolidinone	D-alanyl-D-alanine terminus of cell wall precursors / 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (glycopeptide antibiotic class)

1. Astellas Pharma Europe B.V. · 2 drugs in this class
2. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
3. Kurobe LLC · 1 drug in this class
4. Major Extremity Trauma Research Consortium · 1 drug in this class
5. Savara Inc. · 1 drug in this class